English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/216350
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

The role of ACKR3 in breast, lung, and brain cancer

AuthorsNeves, María; Fumagalli, Amos; Van den Bor, Jelle; Marin, Philippe; Smit, Martine J.; Mayor Méndez, Federico Jr.
Issue Date30-Jan-2019
PublisherAmerican Society for Pharmacology and Experimental Therapeutics
CitationMolecular Pharmacology 96: 819- 825 (2019)
AbstractRecent reports regarding the significance of chemokine receptors in disease have put a spotlight on atypical chemokine receptor 3 (ACKR3). This atypical chemokine receptor is overexpressed in numerous cancer types and has been involved in the modulation of tumor cell proliferation and migration, tumor angiogenesis, or resistance to drugs, thus contributing to cancer progression and metastasis occurrence. Here, we focus on the clinical significance and potential mechanisms underlying the pathologic role of ACKR3 in breast, lung, and brain cancer and discuss its possible relevance as a prognostic factor and potential therapeutic target in these contexts.
Publisher version (URL)http://dx.doi.org/10.1124/mol.118.115279
URIhttp://hdl.handle.net/10261/216350
DOIhttp://dx.doi.org/10.1124/mol.118.115279
Identifiersdoi: 10.1124/mol.118.115279
issn: 1521-0111
Appears in Collections:(CBM) Artículos
Files in This Item:
File Description SizeFormat 
MayorJrF_TheRoleofACKR3.pdf482,5 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.